Liver Diseases  >>  GS 9256  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
GS 9256 / Gilead
NCT01225380 / 2010-020911-35: A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

Checkmark EASL 2012
Apr 2012 - Apr 2012: EASL 2012
Completed
2b
324
US, Canada, Europe
GS-9190, GS-9256, Pegasys®, Copegus®, GS-9190 placebo, GS-9256 placebo
Gilead Sciences
Chronic Hepatitis C Infection
01/13
09/13
NCT01072695 / 2009-013690-18: Efficacy and Safety Study of GS-9256 and GS-9190 Alone and in Combination With Ribavirin for 28 Days in Patients With Chronic Hepatitis C Virus Infection

Checkmark EASL 2012
Mar 2011 - Mar 2011: EASL 2012
Completed
2
46
Europe
GS-9256, GS-9190, Ribavirin, COPEGUS, Peginterferon alfa-2a, Pegasys
Gilead Sciences
HCV Infection
10/10
01/12

Download Options